Pfizer and BioNTech mentioned on Wednesday that they’ve reached an settlement with a South African vaccine producer, beginning subsequent yr, to deal with the ultimate phases of producing for doses of their Covid shot that will likely be equipped completely to African nations.
The deal represents the primary time Pfizer’s Covid vaccine will likely be partly produced in Africa and it may ultimately assist improve provide to a continent the place months of extreme vaccine shortages have resulted in solely about 1.5 % of individuals being totally immunized.
However the settlement comes with caveats that may considerably restrict its influence at a time when the fast-spreading Delta variant has pushed a surge in infections and hospitalizations and despatched the continent into probably the most devastating section of its pandemic.
Crucially, the South African producer, Biovac, will solely be dealing with distribution and “fill-finish” — the ultimate section of the manufacturing course of, throughout which the vaccine is positioned in vials and packaged for transport. It’ll depend on Pfizer services in Europe to make the vaccine substance and ship it to its Cape City facility.
Public well being activists have referred to as on Pfizer and different main vaccine producers to switch their expertise to native producers in poorer elements of the world in order to ramp up manufacturing and alleviate shortages. Sharing recipes on this approach can both be voluntary or compelled.
Matthew Kavanagh, director of the World Well being Coverage and Politics Initiative at Georgetown College, referred to as Wednesday’s settlement “deeply disappointing.”
“What now we have seen from all of those licensing agreements that solely are fill-finish and maintain the complete manufacturing capability to high-income-country producers is that they proceed to simply perpetuate the inequalities in distribution,” Mr. Kavanagh mentioned.
An organization spokeswoman, Pamela Eisele, mentioned that in making an attempt to quickly scale up Covid vaccine manufacturing, Pfizer is “primarily specializing in a number of current websites, trying to exterior contract producers to help the essential fill-and-finish and distribution steps.”
Pfizer has pledged that it’s going to provide two billion doses of its vaccine to low- and middle-income international locations by way of varied channels by the tip of 2022, however up to now, solely a small fraction of these doses have been delivered.
Pfizer mentioned that efforts would start instantly to switch expertise and set up the required tools at Biovac’s facility. Pfizer mentioned the plant would be capable to fill-finish greater than 100 million doses yearly at full capability, although it didn’t say when that might be reached. These doses will likely be equipped solely to the 55 member states that make up the African Union, the corporate mentioned.
To folks “who’ve expressed concern that Africa is being left behind partially because of lack of vaccine manufacturing, I need to say that we hear you,” Pfizer’s chief government, Dr. Albert Bourla, mentioned in ready remarks to a gathering placed on by the World Commerce Group on Wednesday.
However Mr. Kavanagh mentioned he was apprehensive that Pfizer wouldn’t ship sufficient drug substance to Cape City, particularly if rich international locations sought third booster pictures for his or her populations. In that situation, he mentioned, “what chances are it that a lot of the drug substance goes to shift to Africa to do first vaccinations as an alternative of doing boosters in high-income international locations that pay extra and have political energy to demand it?”